MedTrace Logo

Low Dose Niacin (Vitamin B3) for Parkinson's Disease

NCT03808961 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-03-04

Study results available
· View outcomes & findings →

Summary

(1) To examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 18 months of vitamin B3(niacin or niacinamide) supplementation may reduce the inflammation and/or improve PD motor and non-motor symptoms.

Conditions

Interventions

DIETARY_SUPPLEMENT

Niacin

100mg tablets twice daily

DIETARY_SUPPLEMENT

Niacinamide

100mg tablets twice daily

OTHER

Placebo

Placebo tablet twice daily

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Chandramohan Wakade, MBBS · Charlie Norwood VA Medical Center, Augusta, GA

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-11-01
Completion
2023-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808961 on ClinicalTrials.gov